Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma
Jeffrey Sulpher(BC Cancer Agency), Paul Wheatley‐Price(University of Ottawa), Scott Owen(McGill University Health Centre), Marcio M. Gomes, Frances A. Shepherd(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), Christina M. Canil(University of Ottawa), Henrique Hon(University Health Network), Kimberly Tobros(University Health Network), Harman Sekhon(University of Ottawa), Elham Sabri(Ottawa Hospital)
Cited by 8
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k